Tumor-reactive T cells (TR-T) in the peripheral blood of cancer patients undergo phenotypic changes during immune checkpoint inhibitor (ICI) therapy, which might predict therapeutic outcomes. Here authors follow the phenotypes of paired tumor-infiltrating and peripheral CD8 + T cells longitudinally from patients with non-small-cell lung cancer undergoing ICI treatment by single-cell RNA and T cell receptor sequencing and identify specific markers for circulating TR-Ts and for ICI response.
- Katsuhiro Ito
- Kei Iida
- Tomonori Yaguchi
